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enal Artery Revascularization
s There a Rationale to Perform?*
ebabrata Mukherjee, MD, FACC, FSCAI
exington, Kentucky
enal artery stenosis is a common finding in patients with
therosclerotic vascular disease (1). Among patients with
enal artery stenosis, more than 90% are atherosclerotic in
ature, which typically involves the ostium and the proximal
ortion of the main renal artery with plaque extending into
he peri-renal aorta (1). The prevalence of atherosclerotic
enal artery stenosis (ARAS) increases with age, presence of
iabetes, peripheral arterial disease, coronary artery disease,
ypertension, and dyslipidemia. Fibromuscular dysplasia, a
istant second in the etiology of renal artery stenosis
ccounts for 10% of cases and is typically seen in young
nd middle-aged women. As opposed to ARAS, fibromus-
ular dysplasia usually affects the distal two-thirds of the
ain renal artery with a characteristic beaded angiographic
ppearance. Based on epidemiological data, ARAS appears
o be a relatively common clinical finding and is present in
6.8% of patients over the age of 65 years (2) and in 50%
f patients with atherosclerosis elsewhere such as abdominal
ortic aneurysm, aorto-occlusive disease, or lower extremity
cclusive disease (3).
See pages 161 and 175
The goal for either pharmacological or revascularization
herapy of ARAS should be normalization of blood pres-
ure, preservation of renal function, and reduction of the
isk of cardiovascular events. Among those with chronic
enal disease or established nephropathy, one of the more
eaningful end points is the rate of progression to renal
eplacement therapy or dialysis. The availability of safe and
ffective pharmacological agents in the contemporary era
as made the control of blood pressure relatively easier with
rugs than even a few years ago. At the same time, the
mprovements in interventional technology have increased
he technical success rate of renal artery revascularization to
98% in most series. Since, optimal therapy in patients
ith ARAS should include optimal blood pressure control
ith pharmacological agents, modification of cardiovascular
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-r
ions or the American College of Cardiology.
From the Gill Heart Institute, University of Kentucky, Lexington, Kentucky.isk factors, the appropriate use of antiplatelet therapy, and
ipid-lowering therapy, the clinically relevant question then
ecomes which patients are likely to benefit from renal
rtery revascularization and who should be targeted for such
herapies.
In this issue of the Journal, Safian and Madder (4) and
extor et al. (5) offer perspective on the optimal role or lack
f role for renal artery revascularization in patients with
RAS. Since the initial description of renal artery stenting
y Gruntzig in 1978, there have been several contrasting
tudies on the efficacy of percutaneous revascularization for
enal artery stenosis with absence of a consistent benefit.
everal parameters have been suggested to predict clinical
mprovement after renal artery stenting such as the renal
rtery resistance index (6,7), renal size, and renal vein renin
easurement, but the predictive value of such indexes has
ot been consistent. Despite the lack of a consistent benefit,
he number of renal artery stenting procedures has quadru-
led in the last decade (8). It, therefore, would be logical to
ry and understand the rationale for these procedures and try
nd define the patient cohort most likely to benefit from
enal artery stenting. To this end, Safian and Madder (4)
ffer a new classification for ARAS stratifying patients into
hose with and without nephropathy (type 1/2) and those
ith and without renal ischemia (type A/B). Based on this
lassification, the authors suggest that for patients with no
ephropathy and normal renal blood flow (type 1A), they
ould intensify the antihypertensive regimen and follow
atients clinically for the development of vital organ injury.
hey further suggest that the best candidates for revascu-
arization are those with minimal or no nephropathy and
vidence of renal ischemia (type 1B), and the worst candi-
ates are those with advanced nephropathy (type 2), espe-
ially if renal ischemia is absent (type 2A). It should be
oted that the predictive ability of tests currently used for
ssessment of renal ischemia have not been well studied and
ill need further objective testing based on clinical hard end
oints to validate this approach. The authors contention
hat patients with severe bilateral ARAS, minimal or no
ephropathy, renal ischemia (type 1B), and cardiovascular
njury are ideal candidates for renal revascularization is
onsistent with current American College of Cardiology
ACC)/American Heart Association guidelines for the
anagement of patients with peripheral arterial disease (2).
hese guidelines state that ARAS and unexplained pulmo-
ary edema and/or recurrent heart failure are the only class
recommendations for renal artery revascularization.
Textor et al. (5) appropriately point out the lack of
vidence of benefit with renal artery stenting and further
numerate the limitation of the studies to date including
isual estimates of the degree of stenosis, significant cross-
ver to the interventional arm, lack of standardized methods
o assess the status of the intrarenal microcirculation, and
enal hemodynamic and functional reserve. They also de-
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Editorial Comment
184cribe the intrinsic differences between the coronary and
eripheral circulation and the renal circulation. Unlike
lood vessels supplying the heart or brain, the vessels to the
idney deliver a vast excess of oxygenated blood, far more
han needed for basal metabolic demands, and the kidneys
ay be less susceptible to moderate changes in blood flow
ompared with other organs.
Both Safian and Madder (4) and Textor et al. (5) suggest
he need for appropriately designed randomized clinical
rials to further define the role of renal artery revasculariza-
ion and identify the cohort likely to benefit after renal artery
evascularization. The ongoing CORAL (Cardiovascular Out-
omes in Renal Atherosclerotic Lesions) study will compare
he effect of optimal medical therapy alone to stenting with
ptimal medical therapy, on a composite of cardiovascular and
enal end points: cardiovascular or renal death, myocardial
nfarction, hospitalization for congestive heart failure, stroke,
oubling of serum creatinine level, and need for renal replace-
ent therapy in 1,080 patients. This trial has the potential to
elp us understand any incremental benefits of renal artery
evascularization on clinical end points above and beyond
ontemporary optimal medical therapy. Two recent trials, the
TAR (Stenting in Renal Dysfunction Caused by Atheroscle-
otic Renal Artery Stenosis) study and the ASTRAL (Angio-
lasty and Stent for Renal Artery Lesions) study have at-
empted to assess the effect of revascularization on the
rogression of chronic kidney disease. The ASTRAL trial
resented at the Society for Cardiovascular Angiography
nterventions-ACC i2 Summit/ACC 2008 reported that renal
evascularization did not improve serum creatinine, systolic
lood pressure, renal events (such as acute renal failure or
ialysis), mortality, or overall vascular events (9). The results of
he STAR study have not been reported.
Based on the reviews by Safian and Madder (4) and
extor et al. (5) and available data, several observations can
e made regarding renal artery revascularization. First, the
ajority of patients with ARAS do not have renovascular
ypertension explaining the low cure rate of hypertension
fter technically successful renal artery revascularization;
econdly, all patients with ARAS should be treated with
vidence-based secondary preventative therapies such as
ntiplatelet agents, statins, and optimal blood-pressure-
owering agents; thirdly, only a subset of patients with
RAS likely benefit from renal artery stenting, and identi-
cation of this cohort is paramount to long-term benefits
rom renal artery revascularization, and, finally, trials such as
he CORAL study will likely help define the role of renal
rtery revascularization in the future. At this point, it seems
rudent to select patients carefully for renal revasculariza-
ion based on objective evidence of renal ischemia without
vidence of significant parenchymal renal disease or ne-
hropathy. The current ACC/American Heart Association
uidelines are a reasonable reference point for which pa-
ients to assess for ARAS and those likely to benefit from revascularization. As stated before, it is imperative that
hese patients receive optimal secondary preventative ther-
py to reduce future cardiovascular events (10). A national
egistry that collects data on all patients undergoing renal
rtery intervention possibly under the auspices of ACC-
ational Cardiovascular Data Registry may prevent overuse
f renal artery revascularization and at the same time help us
earn in the “real world” setting which patients benefits and
ho may actually do worse after these procedures. Given the
ack of benefit in most cases, physicians may serve them-
elves and their patients well by exercising appropriate
aution before proceeding with renal artery stenting.
eprint requests and correspondence: Dr. Debabrata Mukher-
ee, Gill Heart Institute, Division of Cardiovascular Medicine,
niversity of Kentucky, 900 South Limestone Street, 326 Weth-
ngton Building, Lexington, Kentucky 40536. E-mail:
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